Valentine’s Day for people with multiple sclerosis: promoting brain repair through remyelination
Clinical Neurology, Regenerative Medicine, Neuroimmunology and seminar by Professor Alasdair Coles, Department of Clinical Neurosciences, University of Cambridge
Hosted by Cambridge Neuro
Tuesday 15:00–16:10 London (GMT+0)
Recording available
Abstract
Current disease-modifying therapies in multiple sclerosis are all focused on suppressing the inflammatory phase of the disease. This has been extremely successful, and it is doubtful that significantly more efficacious anti-inflammatory treatments will be found. However, it remains the case that people with relapsing-remitting multiple sclerosis acquire disability on treatment, and enter the secondary progressive phase. I argue that we now need treatments that prevent neuronal degeneration. The most promising approach is to prevent axons degenerating by remyelination. Since the discovery that the adult brain contains stem cells which can remyelinate, the problem now is how to promote endogenous remyelination, and how to know when we have achieved this! We have successfully identified one drug which promotes remyelination but unfortunately it is too toxic for use in the clinic. So the hunt continues.
Topics
Related seminars
- Video page · May 16, 2023Niamh McNamahara, U of Edinburgh / Netherlands Institute of Neuroscience
ASO RNA splice modulating therapies for genetic brain disorders
Video page · Jan 25, 2022Willeke van Roon-Mom, University of Leiden, the Netherlands
More from Cambridge Neuro
All talksImmunosuppression for Parkinson's disease - a new therapeutic strategy?
Video page · May 30, 2023Caroline Williams-GrayFeedback control in the nervous system: from cells and circuits to behaviour
Video page · May 16, 2023Timothy O'LearyTargeting Maladaptive Emotional Memories to Treat Mental Health Disorders: Insights from Rodent Models
Video page · May 9, 2023Amy MiltonFragile minds in a scary world: trauma and post traumatic stress in very young children
Video page · Mar 14, 2023Tim Dalgleish